• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants

tetano

Editor, Senior Moderator
Nat Commun


. 2023 Jun 3;14(1):3235.
doi: 10.1038/s41467-023-38867-x. Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants

Ana S Gonzalez-Reiche[SUP] 1 [/SUP], Hala Alshammary[SUP] 2 3 [/SUP], Sarah Schaefer[SUP] 4 [/SUP], Gopi Patel[SUP] 4 [/SUP], Jose Polanco[SUP] 2 3 [/SUP], Juan Manuel Carreño[SUP] 2 3 [/SUP], Angela A Amoako[SUP] 2 3 [/SUP], Aria Rooker[SUP] 2 3 [/SUP], Christian Cognigni[SUP] 2 3 [/SUP], Daniel Floda[SUP] 1 [/SUP], Adriana van de Guchte[SUP] 1 [/SUP], Zain Khalil[SUP] 1 [/SUP], Keith Farrugia[SUP] 1 [/SUP], Nima Assad[SUP] 5 [/SUP], Jian Zhang[SUP] 1 [/SUP], Bremy Alburquerque[SUP] 1 5 [/SUP]; PARIS/PSP study group; Levy A Sominsky[SUP] 2 3 [/SUP], Charles Gleason[SUP] 2 3 [/SUP], Komal Srivastava[SUP] 2 3 [/SUP], Robert Sebra[SUP] 1 6 7 8 [/SUP], Juan David Ramirez[SUP] 9 10 [/SUP], Radhika Banu[SUP] 9 [/SUP], Paras Shrestha[SUP] 9 [/SUP], Florian Krammer[SUP] 2 3 9 [/SUP], Alberto Paniz-Mondolfi[SUP] 9 [/SUP], Emilia Mia Sordillo[SUP] 11 [/SUP], Viviana Simon[SUP] 12 13 14 15 16 [/SUP], Harm van Bakel[SUP] 17 18 19 [/SUP]



Collaborators, Affiliations
Abstract

Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported in immune-compromised individuals and people undergoing immune-modulatory treatments. Although intrahost evolution has been documented, direct evidence of subsequent transmission and continued stepwise adaptation is lacking. Here we describe sequential persistent SARS-CoV-2 infections in three individuals that led to the emergence, forward transmission, and continued evolution of a new Omicron sublineage, BA.1.23, over an eight-month period. The initially transmitted BA.1.23 variant encoded seven additional amino acid substitutions within the spike protein (E96D, R346T, L455W, K458M, A484V, H681R, A688V), and displayed substantial resistance to neutralization by sera from boosted and/or Omicron BA.1-infected study participants. Subsequent continued BA.1.23 replication resulted in additional substitutions in the spike protein (S254F, N448S, F456L, M458K, F981L, S982L) as well as in five other virus proteins. Our findings demonstrate not only that the Omicron BA.1 lineage can diverge further from its already exceptionally mutated genome but also that patients with persistent infections can transmit these viral variants. Thus, there is, an urgent need to implement strategies to prevent prolonged SARS-CoV-2 replication and to limit the spread of newly emerging, neutralization-resistant variants in vulnerable patients.


 
Back
Top Bottom